Get the latest news, insights, and market updates on ANGO (AngioDynamics, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List
LATHAM, N.Y., October 13, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its NanoKnife System has been selected as one of TIME's 2025 Best Inventions. The annual list celebrates groundbreaking products and technologies that are transforming how people live, work, and receive care. Oct 13, 2025 - $ANGO
AngioDynamics Eyes Growth Despite Tariffs
AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance. Canaccord Genuity analysts, led by John Young, reiterated their Buy rating on AngioDynamics and increased their price forecast to $18 from $17, citing growth across its portfolio and expectations for positive cash flow in fiscal 2026. First-quarter revenue rose 12.1% to $75.7 million, above consensus, led by a 26.2% jump in Med-Tech sales. Gros Oct 3, 2025 - $ANGO
AngioDynamics (ANGO): Losses Worsen, but Forecasted 62% Earnings Growth Challenges Bearish Narratives
AngioDynamics (ANGO) continues to report negative net profit margin, with losses accelerating at an average rate of 1.3% per year over the last five years and no margin improvement reported in the last twelve months. While revenue is forecast to grow at 6.3% per year, which is below the 9.8% growth projected for the broader US market, earnings are expected to rebound sharply, with a projected growth rate of 62.02% annually and profitability anticipated within the next three years. For... Oct 3, 2025 - $ANGO
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
LATHAM, N.Y., October 02, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025. Oct 2, 2025 - $ANGO
AngioDynamics: Fiscal Q1 Earnings Snapshot
LATHAM, N.Y. (AP) — AngioDynamics Inc. ANGO) on Thursday reported a loss of $10.9 million in its fiscal first quarter. The Latham, New York-based company said it had a loss of 26 cents per share. Oct 2, 2025 - $ANGO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple